AWM Investment Company, Inc., a Delaware-based investment adviser, has filed an amended Schedule 13G with the SEC, indicating a 9.2% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reports that AWM holds sole voting and dispositive power over 12,691,213 shares of Clene's common stock. Additionally, AWM has investment power over a significant number of warrants to purchase Clene's common stock, held by various funds under its advisement. The warrants are exercisable provided they do not push AWM's ownership above 10% of Clene's outstanding shares. The principal business address for AWM is listed in New York, NY, and the filing was signed by Adam Stettner, Executive Vice President of AWM, on February 13, 2024.

AWM Investment Company, Inc., a Delaware-based investment adviser, has filed an amended Schedule 13G with the SEC, indicating a 9.2% ownership stake in Clene Inc., a biopharmaceutical company. The filing, dated December 31, 2023, reports that AWM holds sole voting and dispositive power over 12,691,213 shares of Clene's common stock. Additionally, AWM has investment power over a significant number of warrants to purchase Clene's common stock, held by various funds under its advisement. The warrants are exercisable provided they do not push AWM's ownership above 10% of Clene's outstanding shares. The principal business address for AWM is listed in New York, NY, and the filing was signed by Adam Stettner, Executive Vice President of AWM, on February 13, 2024.